The present invention discloses a blood coagulation-promoting silk fibroin-polypeptide electrospun membrane and a preparation method thereof. The electrospun membrane is made by using silkworm silk fibroin as a carrier and adding the polypeptide GPRPPSEHLQIT. It is mainly used for promoting blood coagulation, and is a blood coagulation material that can targetedly bind to human fibrinogen. The preparation method includes the steps of dissolving, filtering, dialyzing, concentrating and freeze-drying silkworm cocoons after degumming to obtain silk fibroin freeze-dried powder. The polypeptide used in the present invention is a polypeptide obtained by self-screening. Compared with other polypeptides, it can specifically targetedly bind to human fibrinogen.

A hemostatic material includes a lipid that can accelerate adhesion or aggregation of platelets even if the lipid does not carry a protein or a peptide involved in adhesion or aggregation of platelets such as GPIb and H12 and, to achieve the object, provides a hemostatic material including a water-insoluble base and a lipid supported on a surface of the base, wherein the lipid includes one or two or more anionic lipids.

A hemostatic material includes a lipid that can accelerate adhesion or aggregation of platelets even if the lipid does not carry a protein or a peptide involved in adhesion or aggregation of platelets such as GPIb and H12 and, to achieve the object, provides a hemostatic material including a water-insoluble base and a lipid supported on a surface of the base, wherein the lipid includes one or two or more anionic lipids.

The present invention relates to biocompatible compositions comprising one or more crystallin proteins, and the use of such compositions in therapeutic and research methods, for example in surgical methods, in sustained release drug delivery, and in cell-based methods.

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent, agitating and shearing said suspension in a high shear mixing reactor, adding water to allow particles to agglomerate, allowing the non-aqueous solvent to evaporate, drying and sieving the composition; and thus forming the powdered hemostatic composition.

Methods for producing a fibrin matrix comprising a fusion peptide are described herein. In some embodiments, the method includes providing three different components, including a first component containing fibrinogen or a fibrinogen precursor and optionally, transglutaminase or a transglutaminase precursor, a second component containing thrombin or a thrombin precursor, and a third component containing a fusion peptide. In these embodiments, neither the first component nor the second component includes the fusion peptide. In some embodiments, the first or second components are premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising a covalently linked fusion peptide. The mixing is carried out in a time frame of not more than 5 days. A kit for producing the fibrin matrix comprising a covalently linked fusion peptide is also described herein.

Provided is a hemostatic composition comprising trypsin and zeolite, wherein pore channels of the zeolite are micropores, the zeolite contains divalent metal cations, and the mass ratio of the trypsin to the zeolite is 1:200-4:10. In the present invention, the trypsin specifically binds to the zeolite, allowing the trypsin to maintain a certain conformation on the surface of the zeolite and to obtain a higher procoagulant activity, thereby obtaining a hemostatic composition with an excellent blood coagulation effect. The hemostatic composition of the present invention has the advantages of a simple preparation method, low cost and convenient use, and can be widely used in hemostasis during trauma and operations, especially in emergent hemostasis in hemophilia patients.

Described are photocurable liquid adhesives, kits for preparing photocurable liquid adhesives, and methods for their preparation and use. Kits can include first and second components that can be mixed to prepare a photocurable liquid adhesive. The first component can include a liquid preparation including an aqueous liquid, one or more polymers containing phenolic groups, and a photoactivatable metal ligand complex. The second component can include an electron acceptor. Mixing the first component and the second component can create a photocurable liquid adhesive. The first and second components can be packaged in containers such as syringes, and the kits can include the containers and a cannulated coupler for fluidly coupling the containers to mix the container contents to prepare the photocurable liquid adhesive. A syringe dispensing tip and/or a light source for curing the photocurable liquid adhesive can also be included in the kits. Advantageous photocurable liquid adhesives are described that, absent curing, remain in flowable liquid form during typical temperatures of storage and use. The adhesives can include in or as a phenolic group-containing polymer component one or more of collagen, phenol enriched collagen, gelatin, phenol enriched gelatin, a collagen peptide composition, or a phenol enriched collagen peptide composition.

Provided are a biomedical tape, a preparation method thereof and use thereof. The biomedical tape comprises a hydrogel carrier in dry state and a functional nanomaterial encapsulated within the hydrogel carrier in dry state, and the hydrogel carrier in dry state comprises a thin film body of hyaluronic acid hydrogel and a dopamine-modified polyacrylic acid permeated into a surface of the thin film body of hyaluronic acid hydrogel. The preparation method for the biomedical tape comprises: preparing a hyaluronic acid hydrogel with the functional nanomaterial dispersed therein, and drying and curing the hydrogel to form a film to obtain the thin film body of hyaluronic acid hydrogel; and preparing a dopamine-modified polyacrylic acid solution, and permeating the solution into a surface of the thin film body of hyaluronic acid hydrogel by coating to obtain the biomedical tape.

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.